Parastoo Bahrami Dahi

Memorial Sloan Kettering Cancer Center

*This is an algorithmically generated author record based on publicly available information.

See Latest Publications

See Most Cited Publications

SciProfiles

ORCID Profile

Google Scholar

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Memorial Sloan Kettering Cancer Center

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years

Research Subjects

Research Interests

Parastoo Bahrami Dahi has a total of 751 co-authors. Here are the top co-authors by number of shared publications:

Miguel-Angel Perales
Memorial Sloan Kettering Cancer Center, New York, New York, United States
68 shared publications
Gunjan L. Shah
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, United States
58 shared publications
Richard J. Lin
Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, USA
52 shared publications
Roni Shouval
Memorial Sloan Kettering Cancer Center, New York, New York, United States
46 shared publications
Gilles Salles
Memorial Sloan Kettering Cancer Center, New York, NY
40 shared publications
Michael Scordo
Adult Bone Marrow Transplant Service, Department of Medicine Memorial Sloan Kettering Cancer Center New York New York USA
38 shared publications

Latest Publications

Sort by

Open Access
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
Clinical outcomes stratified by CD19 MFI expression in patients treated with tisa-cel.
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S1 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
Clinical outcomes stratified by CD19 MFI expression in patients treated with tisa-cel.
Open Access
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
Clinical outcomes stratified by CD19 rMFI expression in axi-cel and liso-cel patients with tumor samples obtained within 60 days before CAR-T infusion.
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S2 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
Clinical outcomes stratified by CD19 rMFI expression in axi-cel and liso-cel patients with tumor samples obtained within 60 days before CAR-T infusion.
Open Access
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S10 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
Flow cytometry gating strategy for quantitative assessment of CD19 expression in a lymphoma sample.
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S10 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
Flow cytometry gating strategy for quantitative assessment of CD19 expression in a lymphoma sample.
Open Access
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
Representative examples of CD19 expression by flow cytometry and immunohistochemistry in lymphoma-involved samples.
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S11 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
Representative examples of CD19 expression by flow cytometry and immunohistochemistry in lymphoma-involved samples.
Open Access
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
Time-dependent ROC analysis of CD19 expression by flow cytometry in axi-cel and liso-cel patients.
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S3 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
Time-dependent ROC analysis of CD19 expression by flow cytometry in axi-cel and liso-cel patients.
Open Access
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
Progression-free survival by qualitative pathology review in axi-cel and liso-cel patients.
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S4 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
Progression-free survival by qualitative pathology review in axi-cel and liso-cel patients.
Open Access
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
Correlation of CD19 rMFI by flow cytometry and lymphoma infiltration in axi-cel or liso-cel–treated patients.
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S5 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
Correlation of CD19 rMFI by flow cytometry and lymphoma infiltration in axi-cel or liso-cel–treated patients.
Open Access
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
Relationship between WES-derived tumor purity and deconvolution-derived immune cell fractions.
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S6 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
Relationship between WES-derived tumor purity and deconvolution-derived immune cell fractions.
Open Access
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
CD19 rMFI by flow and best response, pre and post-CAR-T, in paired samples of patients receiving axi-cel or liso-cel.
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S7 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
CD19 rMFI by flow and best response, pre and post-CAR-T, in paired samples of patients receiving axi-cel or liso-cel.
Open Access
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
CD20 rMFI and CD22 rMFI by flow pre and post-CAR-T, in paired samples of patients receiving axi-cel or liso-cel.
Website
Google Scholar
- 3 November 2026
- Published by American Association for Cancer Research (AACR)
Open Access
Figure S8 from Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
by Magdalena Corona, Aaron Gillmor, Kimon V. Argyropoulos, Teng Fei, Maria Isabel Sotelo-Alva, Mohammad Alhomoud, Parastoo B. Dahi, Anthony F. Daniyan, Mark T.A. Donoghue, Sigrun Einarsdottir, et al.
CD20 rMFI and CD22 rMFI by flow pre and post-CAR-T, in paired samples of patients receiving axi-cel or liso-cel.

Show all